• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by ResMed Inc. (Amendment)

    2/10/22 8:32:59 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care
    Get the next $RMD alert in real time by email
    SC 13G/A 1 tv01782-resmedinc.htm SCHEDULE 13G/A resmedinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 10)*

    Name of issuer:  ResMed Inc.

    Title of Class of Securities:  Common Stock and CDI

    CUSIP Number:  761152107

    Date of Event Which Requires Filing of this Statement: December 31, 2021

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  761152107

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    751,220

    7.  SOLE DISPOSITIVE POWER

    15,014,167

    8.  SHARED DISPOSITIVE POWER

    1,105,762

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    16,119,963

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    11.06%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    ResMed Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    9001 Spectrum Center Boulevard
    San Diego, CA 92123

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock and CDI

    Item 2(e) - CUSIP Number

    761152107

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    * The Vanguard Group, Inc. held 5,067,142 Chess Depository Interests (“CDIs”) and 15,613,249 shares of Common Stock as of the date of event which requires this filing statement. Each CDI share held represents 0.1 shares of Common Stock.

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 9, 2022

    By /s/ Christine M. Buchanan
    Name: Christine M. Buchanan
    Title:  Principal

    Get the next $RMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RMD

    DatePrice TargetRatingAnalyst
    3/19/2025$280.00Overweight
    Morgan Stanley
    3/19/2025Overweight
    Morgan Stanley
    1/16/2025Buy
    Goldman
    1/10/2025$252.00Neutral
    Piper Sandler
    12/13/2024$250.00Hold
    Stifel
    9/24/2024$280.00Outperform
    Robert W. Baird
    9/18/2024$180.00Peer Perform → Underperform
    Wolfe Research
    9/4/2024Buy → Hold
    Needham
    More analyst ratings

    $RMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Resmed Champions Sleep Health as The Official Sleep Partner of The Qatar Airways British & Irish Lions Tour to Australia 2025

      SAN DIEGO and LONDON and DUBLIN and SYDNEY, May 15, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)), the leading health technology company focused on sleep, breathing, and care delivered in the home, has been named the Official Sleep Partner of the Qatar Airways British & Irish Lions Tour to Australia. The Tour brings rugby fans' dreams to life over a six-week period. For the first time in 12 years, The Lions squad, alongside an estimated 40,000 fans, will battle it out with the Wallabies, Super Rugby Pacific teams, and exhibition sides in six cities across Australia. As the Official Sleep Partner, Resmed will launch ‘Tackle Your Sleep,' a digital and content focused campaign featu

      5/15/25 9:00:00 AM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • Resmed Acquires VirtuOx

      SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced it has acquired VirtuOx, a leading independent diagnostic testing facility (IDTF) for sleep, respiratory, and cardiac conditions. The acquisition reflects Resmed's commitment to improving the way care is delivered—by making it more accessible, more coordinated, and more patient friendly. With VirtuOx's at-home diagnostic services, Resmed will be better positioned to support patients earlier in their journey and help healthcare providers and homecare companies deliver care in a simpler, more connected wa

      5/1/25 9:00:00 AM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2025

      Year-over-year revenue grows 8%, operating profit up 14%, non-GAAP operating profit up 13%Operating cash flow of $579 million Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE:RMD, ASX: RMD)) today announced results for its quarter ended March 31, 2025. Third Quarter 2025 HighlightsAll comparisons are to the prior year period Revenue increased by 8% to $1.3 billion; up 9% on a constant currency basis Gross margin improved 140 bps to 59.3%; non-GAAP gross margin improved 140 bps to 59.9%Income from operations increased 14%; non-GAAP income from operations up 13

      4/23/25 4:05:00 PM ET
      $RMD
      Medical/Dental Instruments
      Health Care

    $RMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Morgan Stanley initiated coverage on ResMed with a new price target

      Morgan Stanley initiated coverage of ResMed with a rating of Overweight and set a new price target of $280.00

      3/19/25 10:13:23 AM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • Morgan Stanley initiated coverage on ResMed

      Morgan Stanley initiated coverage of ResMed with a rating of Overweight

      3/19/25 8:18:03 AM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • Goldman initiated coverage on ResMed

      Goldman initiated coverage of ResMed with a rating of Buy

      1/16/25 7:53:14 AM ET
      $RMD
      Medical/Dental Instruments
      Health Care

    $RMD
    Financials

    Live finance-specific insights

    See more
    • Resmed Acquires VirtuOx

      SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced it has acquired VirtuOx, a leading independent diagnostic testing facility (IDTF) for sleep, respiratory, and cardiac conditions. The acquisition reflects Resmed's commitment to improving the way care is delivered—by making it more accessible, more coordinated, and more patient friendly. With VirtuOx's at-home diagnostic services, Resmed will be better positioned to support patients earlier in their journey and help healthcare providers and homecare companies deliver care in a simpler, more connected wa

      5/1/25 9:00:00 AM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2025

      Year-over-year revenue grows 8%, operating profit up 14%, non-GAAP operating profit up 13%Operating cash flow of $579 million Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE:RMD, ASX: RMD)) today announced results for its quarter ended March 31, 2025. Third Quarter 2025 HighlightsAll comparisons are to the prior year period Revenue increased by 8% to $1.3 billion; up 9% on a constant currency basis Gross margin improved 140 bps to 59.3%; non-GAAP gross margin improved 140 bps to 59.9%Income from operations increased 14%; non-GAAP income from operations up 13

      4/23/25 4:05:00 PM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • Resmed to Report Third Quarter Fiscal 2025 Earnings on April 23, 2025

      SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)) today announced it plans to release financial and operational results for the third quarter of fiscal year 2025 on Wednesday, April 23, 2025, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details:  •Location:https://investor.resmed.com •Date:Wednesday, April 23, 2025 •Time:1:30 p.m. PDT / 4:30 p.m. EDT •International:London, Wednesday, April 23, 2025, 9:30 p.m. BST   Sydney, Thursday, April 24, 2025, 6:30 a.m. AEST Please note,

      4/2/25 4:05:00 PM ET
      $RMD
      Medical/Dental Instruments
      Health Care

    $RMD
    SEC Filings

    See more
    • SEC Form 144 filed by ResMed Inc.

      144 - RESMED INC (0000943819) (Subject)

      5/7/25 8:12:48 PM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • SEC Form 8-K filed by ResMed Inc.

      8-K - RESMED INC (0000943819) (Filer)

      4/23/25 4:05:31 PM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • SEC Form 144 filed by ResMed Inc.

      144 - RESMED INC (0000943819) (Subject)

      2/5/25 6:57:52 PM ET
      $RMD
      Medical/Dental Instruments
      Health Care

    $RMD
    Leadership Updates

    Live Leadership Updates

    See more
    • Resmed Names Salli Schwartz as Chief Investor Relations Officer

      SAN DIEGO, April 21, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD), ASX: RMD), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the appointment of Salli Schwartz as Chief Investor Relations Officer, effective April 21, 2025. In this role, Schwartz will lead Resmed's global investor relations function and report to Mick Farrell, Chairman of the Board and CEO. Schwartz is a seasoned executive with more than two decades of experience in a range of finance roles at health tech and financial services organizations. She joins Resmed from Illumina, Inc., where she served as the Head of Investor Relations. In that role, she

      4/21/25 5:00:00 PM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • Jan De Witte joins GHO Capital as Operating Partner

      Jan De Witte joins GHO Capital as Operating Partner Former CEO of Integra LifeSciences with significant strategic and operational experience to support GHO Capital's portfolio London, UK – 11 February 2025: Global Healthcare Opportunities, or GHO Capital Partners LLP ("GHO"), the European specialist investor in global healthcare, is pleased to announce the appointment of Jan De Witte as Operating Partner. Jan is an accomplished senior executive with extensive experience leading international growth and transformation for global technology and life sciences companies. Prior to joining GHO, he was Chief Executive Officer and member of the Board of Directors at Integra LifeSciences (("Integr

      2/11/25 4:30:00 AM ET
      $IART
      $RMD
      Medical/Dental Instruments
      Health Care
    • Incannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board

      NEW YORK and MELBOURNE, Australia, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing combination medicines today announced the appointment of Alison Wimms, Ph.D. as an advisor to its newly formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board where she will represent ResMed. Dr. Wimms brings two decades of sleep medicine industry and research expertise to her advisory role at Incannex. Dr. Wimms holds a Doctor of Philosophy (Ph.D.) in Medicine, and Master of Medicine (Sleep Medicine) and Bachelor of Science degrees from the University of Sydney. "Incannex's

      2/4/25 9:15:00 AM ET
      $IXHL
      $RMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments

    $RMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Farrell Michael J. exercised 8,009 units of ResMed Common Stock at a strike of $101.64 and sold $1,948,003 worth of ResMed Common Stock (8,009 units at $243.23) (SEC Form 4)

      4 - RESMED INC (0000943819) (Issuer)

      5/9/25 11:01:20 AM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • Director Farrell Peter C sold $484,500 worth of ResMed Common Stock (2,000 units at $242.25), decreasing direct ownership by 3% to 71,218 units (SEC Form 4)

      4 - RESMED INC (0000943819) (Issuer)

      5/8/25 5:38:05 PM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Sandercock Brett sold $215,580 worth of ResMed Common Stock (1,000 units at $215.58), decreasing direct ownership by 1% to 89,864 units (SEC Form 4)

      4 - RESMED INC (0000943819) (Issuer)

      4/10/25 6:14:32 PM ET
      $RMD
      Medical/Dental Instruments
      Health Care

    $RMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by ResMed Inc. (Amendment)

      SC 13G/A - RESMED INC (0000943819) (Subject)

      2/10/23 1:36:52 PM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by ResMed Inc. (Amendment)

      SC 13G/A - RESMED INC (0000943819) (Subject)

      2/10/22 5:05:17 PM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by ResMed Inc. (Amendment)

      SC 13G/A - RESMED INC (0000943819) (Subject)

      2/10/22 8:32:59 AM ET
      $RMD
      Medical/Dental Instruments
      Health Care